Leith Al-Hashimi, Jens Klotsche, Sarah Ohrndorf, Timo Gaber, Paula Hoff
Method: Patients who underwent bone densitometry over a 12-month period were analyzed for the proportion of those who also underwent TBS measurement, demographic data, leading diagnoses, bone metabolism parameters, and bone mineral density (BMD) and TBS results.
Results: Data were collected from 292 patients. More than 90% of patients consented to pay-for TBS measurement. Of the patients with a therapeutic indication for antiosteoporotic medication, the decision was influenced by TBS measurement in approximately 40% of cases. We could demonstrate that depending on the underlying disease / risk spectrum (glucocorticoid therapy, rheumatic diseases, endocrinological diseases, previous osteoporosis-typical fractures) a proportion of 21-25.5% of the patients had an inconspicuous BMD measurement with impaired bone quality shown in the TBS measurement.
Discussion: The TBS measurement was very well accepted by the patients. In our MVZ, where numerous patients with secondary osteoporosis are treated, TBS has frequently contributed to the treatment decision.
The measurement of the trabecular bone score (TBS) is not yet widespread. However, for secondary forms of osteoporosis in particular, the presentation of the TBS in addition to bone density measurement is helpful. We summarized the data from the Endokrinologikum Berlin of the TBS measurement over a period of 12 months. We asked ourselves to what extent the measurement, which is subject to a fee, is accepted by the patients and how often it helps us in the therapy decision.
Link of the article: https://www.thieme-connect.com/products/ejournals/html/10.1055/s-0042-1755860